<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">ssrvwqrCSyTn38SyHBy83kL</article-id>
      <article-id pub-id-type="other">00011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000600011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200611</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000600011</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Efeitos da administra&#231;&#227;o de beta-bloqueador na remodela&#231;&#227;o ventricular induzida pelo tabagismo em ratos</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Duarte</surname>
            <given-names>Daniella R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Oliveira</surname>
            <given-names>Lucienne C.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Minicucci</surname>
            <given-names>Marcos F.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Azevedo</surname>
            <given-names>Paula S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsubara</surname>
            <given-names>Beatriz B.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsubara</surname>
            <given-names>Luiz S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Campana</surname>
            <given-names>&#193;lvaro O.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paiva</surname>
            <given-names>Sergio A. R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zornoff</surname>
            <given-names>Leonardo A. M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Botucatu</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Estadual Paulista</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>06</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>6</issue>
      <fpage>479</fpage>
      <lpage>483</lpage>
      <history>
        <date date-type="accepted">
          <day>09</day>
          <month>07</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>29</day>
          <month>05</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>05</day>
          <month>03</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: O papel do sistema adren&#233;rgico na remodela&#231;&#227;o induzida pelo tabagismo &#233; desconhecido. OBJETIVO: Investigar a influ&#234;ncia do propranolol na remodela&#231;&#227;o induzida pela exposi&#231;&#227;o &#224; fuma&#231;a de cigarro. M&#201;TODOS: Ratos foram alocados em tr&#234;s grupos: 1) C, n=10 - animais controle; 2) F, n=10 - animais expostos &#224; fuma&#231;a de cigarro; 3) BB, n=10 - animais expostos &#224; fuma&#231;a de cigarro e que receberam propranolol (40 mg/kg/dia). Ap&#243;s dois meses, os animais foram submetidos a estudo ecocardiogr&#225;fico e morfom&#233;trico. Utilizou-se an&#225;lise de vari&#226;ncia (ANOVA) de uma via (m&#233;dia &#177; desvio padr&#227;o) ou Kruskal-Wallis (mediana e intervalo interquartil). RESULTADOS: O Grupo BB apresentou menor frequ&#234;ncia card&#237;aca que o Grupo F (C = 358 &#177; 74 btm, F = 374 &#177; 53 bpm, BB = 297 &#177; 30; P = 0,02). O Grupo F apresentou maiores di&#226;metros diast&#243;licos (C = 18,6 &#177; 3,4 mm/kg, F = 22,8 &#177; 1,8 mm/kg, BB = 21,7 &#177; 1,8 mm/kg; P = 0,003) e sist&#243;licos (C = 8,6 &#177; 2,1 mmkg, F = 11,3 &#177; 1,3 mm/kg, BB = 9,9 &#177; 1,2 mm/kg; P = 0,004) do ventr&#237;culo esquerdo (VE), ajustado ao peso corporal (PC) e tend&#234;ncia de menor fra&#231;&#227;o de eje&#231;&#227;o (C = 0,90 &#177; 0,03, F = 0,87 &#177; 0,03, BB =0,90 &#177; 0,02; P = 0,07) que o Grupo C. O Grupo BB apresentou tend&#234;ncia de menor rela&#231;&#227;o VE/PC que o Grupo F (C = 1,94 (1,87 - 1,97), F = 2,03 (1,9-2,1) mg/g, BB = 1,89 (1,86-1,94); P = 0,09). CONCLUS&#195;O: A administra&#231;&#227;o de propranolol atenuou algumas vari&#225;veis da remodela&#231;&#227;o ventricular induzida pela exposi&#231;&#227;o &#224; fuma&#231;a do cigarro em ratos.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Beta-antagonistas adren&#233;rgicos</kwd>
        <kwd>remodela&#231;&#227;o ventricular</kwd>
        <kwd>tabagismo</kwd>
        <kwd>ratos</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>20</day>
        <month>07</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> EXPERIMENTAL</p>
    <p>Efeitos da administra&#231;&#227;o de beta-bloqueador na remodela&#231;&#227;o ventricular induzida pelo tabagismo em ratos</p>
    <p>
      <bold>Daniella R. Duarte; Lucienne C. Oliveira; Marcos F. Minicucci; Paula S. Azevedo; Beatriz B. Matsubara; Luiz S. Matsubara; &#193;lvaro O. Campana; Sergio A. R. Paiva; Leonardo A. M. Zornoff</bold>
    </p>
    <p>Faculdade de Medicina de Botucatu, Botucatu, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO: </bold>O papel do sistema adren&#233;rgico na remodela&#231;&#227;o induzida pelo tabagismo &#233; desconhecido. </p>
    <p><bold>OBJETIVO: </bold>Investigar a influ&#234;ncia do propranolol na remodela&#231;&#227;o induzida pela exposi&#231;&#227;o &#224; fuma&#231;a de cigarro. </p>
    <p><bold>M&#201;TODOS: </bold>Ratos foram alocados em tr&#234;s grupos: 1) C, n=10 &#150; animais controle; 2) F, n=10 &#150; animais expostos &#224; fuma&#231;a de cigarro; 3) BB, n=10 &#150; animais expostos &#224; fuma&#231;a de cigarro e que receberam propranolol (40 mg/kg/dia). Ap&#243;s dois meses, os animais foram submetidos a estudo ecocardiogr&#225;fico e morfom&#233;trico. Utilizou-se an&#225;lise de vari&#226;ncia (ANOVA) de uma via (m&#233;dia &#177; desvio padr&#227;o) ou Kruskal-Wallis (mediana e intervalo interquartil). </p>
    <p><bold>RESULTADOS:</bold> O Grupo BB apresentou menor frequ&#234;ncia card&#237;aca que o Grupo F (C = 358 &#177; 74 btm, F = 374 &#177; 53 bpm, BB = 297 &#177; 30; P = 0,02). O Grupo F apresentou maiores di&#226;metros diast&#243;licos (C = 18,6 &#177; 3,4 mm/kg, F = 22,8 &#177; 1,8 mm/kg, BB = 21,7 &#177; 1,8 mm/kg; P = 0,003) e sist&#243;licos (C = 8,6 &#177; 2,1 mmkg, F = 11,3 &#177; 1,3 mm/kg, BB = 9,9 &#177; 1,2 mm/kg; P = 0,004) do ventr&#237;culo esquerdo (VE), ajustado ao peso corporal (PC) e tend&#234;ncia de menor fra&#231;&#227;o de eje&#231;&#227;o (C = 0,90 &#177; 0,03, F = 0,87 &#177; 0,03, BB =0,90 &#177; 0,02; P = 0,07) que o Grupo C. O Grupo BB apresentou tend&#234;ncia de menor rela&#231;&#227;o VE/PC que o Grupo F (C = 1,94 (1,87 &#150; 1,97), F = 2,03 (1,9-2,1) mg/g, BB = 1,89 (1,86-1,94); P = 0,09). </p>
    <p><bold>CONCLUS&#195;O:</bold> A administra&#231;&#227;o de propranolol atenuou algumas vari&#225;veis da remodela&#231;&#227;o ventricular induzida pela exposi&#231;&#227;o &#224; fuma&#231;a do cigarro em ratos. </p>
    <p><bold>Palavras-chave: </bold>Beta-antagonistas adren&#233;rgicos/administra&#231;&#227;o &amp; dosagem, remodela&#231;&#227;o ventricular, tabagismo, ratos.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A remodela&#231;&#227;o card&#237;aca pode ser definida como varia&#231;&#245;es no tamanho, massa, geometria, composi&#231;&#227;o e fun&#231;&#227;o do cora&#231;&#227;o. Esse processo ocorre em resposta a diversos est&#237;mulos, incluindo infarto do mioc&#225;rdio, hipertens&#227;o arterial sist&#234;mica, doen&#231;a valvar e muta&#231;&#245;es gen&#233;ticas<sup>1-3</sup>. Inicialmente, a remodela&#231;&#227;o &#233; processo adaptativo compensat&#243;rio, desde que as altera&#231;&#245;es morfol&#243;gicas podem restaurar ou preservar a fun&#231;&#227;o card&#237;aca em resposta a diferentes agress&#245;es. Cronicamente, entretanto, o processo de remodela&#231;&#227;o resulta em queda progressiva da fun&#231;&#227;o ventricular, sinais e sintomas de insufici&#234;ncia card&#237;aca e morte<sup>1-3</sup>.</p>
    <p>Recentemente, v&#225;rios estudos mostraram que, no modelo do rato, a exposi&#231;&#227;o &#224; fuma&#231;a do cigarro resulta em remodela&#231;&#227;o card&#237;aca, caracterizada por aumento da cavidade ventricular esquerda, hipertrofia dos mi&#243;citos e queda da fun&#231;&#227;o ventricular<sup>4-9</sup>. Contudo, os mecanismos envolvidos nesse fen&#244;meno ainda permanecem por serem determinados. Dentre os mecanismos envolvidos na modula&#231;&#227;o das altera&#231;&#245;es funcionais e morfol&#243;gicas presentes em diferentes modelos de agress&#227;o, a ativa&#231;&#227;o do sistema adren&#233;rgico parece desempenhar papel de destaque<sup>10,11</sup>. Assim, estudos j&#225; mostraram que o uso de beta-bloqueadores atenua a remodela&#231;&#227;o card&#237;aca em diferentes modelos experimentais e cl&#237;nicos<sup>12</sup>. No entanto, os efeitos da administra&#231;&#227;o de beta-bloqueadores na remodela&#231;&#227;o induzida pela exposi&#231;&#227;o &#224; fuma&#231;a do cigarro n&#227;o s&#227;o conhecidos.</p>
    <p>Portanto, o objetivo desse estudo foi investigar a influ&#234;ncia da administra&#231;&#227;o de propranolol na remodela&#231;&#227;o ventricular induzida pela exposi&#231;&#227;o &#224; fuma&#231;a de cigarro em ratos.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>O protocolo experimental do presente trabalho foi aprovado pela Comiss&#227;o de &#201;tica em Experimenta&#231;&#227;o Animal da Faculdade de Medicina de Botucatu, estando em conformidade com os Princ&#237;pios &#201;ticos na Experimenta&#231;&#227;o Animal, adotados pelo Col&#233;gio Brasileiro de Experimenta&#231;&#227;o Animal.</p>
    <p>
      <bold>Protocolo e grupos experimentais</bold>
    </p>
    <p>Ratos Wistar, machos, pesando entre 200 g e 230 g, foram alocados em tr&#234;s grupos experimentais: </p>
    <p>1) Grupo C, n=10 &#150; formado por animais n&#227;o expostos &#224; fuma&#231;a do cigarro; </p>
    <p>2) Grupo F, n=10 &#150; formado pelos animais que foram expostos &#224; fuma&#231;a de cigarro por per&#237;odo de dois meses;</p>
    <p> 3) Grupo BB, n=10 &#150; formado pelos animais que foram expostos &#224; fuma&#231;a de cigarro por per&#237;odo de dois meses e que receberam propranolol (40 mg/kg/dia) dissolvido na &#225;gua de beber. Estudo pr&#233;vio evidenciou que essa dose possui efeitos biol&#243;gicos no modelo do rato<sup>13</sup>. Como a medica&#231;&#227;o estava dilu&#237;da em &#225;gua, foi realizado controle di&#225;rio da ingest&#227;o de ra&#231;&#227;o e &#225;gua pelos animais. </p>
    <p>
      <bold>A exposi&#231;&#227;o ao fumo </bold>
    </p>
    <p>Para expor os animais &#224; fuma&#231;a do cigarro, foi utilizado o m&#233;todo proposto por Wang e cols.<sup>14</sup>, j&#225; padronizado em nosso laborat&#243;rio<sup>4-9</sup>. No fim do per&#237;odo de estudo experimental, os animais foram expostos &#224; fuma&#231;a de quarenta cigarros/dia. Com essa metodologia, a exposi&#231;&#227;o &#224; fuma&#231;a do cigarro resulta em remodela&#231;&#227;o card&#237;aca e piora funcional<sup>4-9</sup>. </p>
    <p>
      <bold>Press&#227;o sist&#243;lica caudal</bold>
    </p>
    <p>A medida da press&#227;o arterial sist&#243;lica (PAS) caudal foi realizada duas semanas antes do sacrif&#237;cio. Os animais fumantes n&#227;o foram submetidos &#224; exposi&#231;&#227;o &#224; fuma&#231;a do cigarro por per&#237;odo de 24 horas antes das aferi&#231;&#245;es. Utilizou-se plestim&#243;grafo de cauda, constitu&#237;do por um pol&#237;grafo (Byo-Sistem PE 300, NARCO) com sensor colocado na regi&#227;o proximal da cauda e um eletroesfigmoman&#244;metro, possibilitando assim o registro gr&#225;fico da press&#227;o arterial. Os animais foram aquecidos em caixa de madeira a 37&#186;C, com o calor gerado por duas l&#226;mpadas de filamentos, por quatro minutos, e transferidos para um suporte cil&#237;ndrico de ferro, especialmente desenhado para permitir a completa exposi&#231;&#227;o da cauda do animal. Na regi&#227;o proximal da cauda foi colocado o sensor (KSM-microfone) ligado ao plestim&#243;grafo. </p>
    <p>
      <bold>Avalia&#231;&#227;o morfol&#243;gica e funcional pelo ecocardiograma</bold>
    </p>
    <p>Vinte e quatro horas ap&#243;s o fim do per&#237;odo de observa&#231;&#227;o, os animais foram submetidos ao estudo ecocardiogr&#225;fico. Utilizou-se equipamento da Philips (modelo HDI 5500) dotado de transdutor multifrequencial at&#233; 12 MHz. As estruturas card&#237;acas foram medidas de acordo com as recomenda&#231;&#245;es da <italic>American Society of Echocardiography</italic><sup>15</sup>. As medidas foram feitas pelo mesmo observador, sem conhecimento a que grupos pertenciam os animais.</p>
    <p>
      <bold>Estudo morfom&#233;trico</bold>
    </p>
    <p>Ap&#243;s o estudo ecocardiogr&#225;fico, os animais foram sacrificados por administra&#231;&#227;o de pentobarbitol. A rela&#231;&#227;o entre o peso dos ventr&#237;culos (esquerdo e direito), ajustado pelo peso corporal dos animais, foi utilizada como par&#226;metro de hipertrofia mioc&#225;rdica<sup>16,17</sup>. As medidas foram feitas pelo mesmo observador, sem conhecimento a que grupos pertenciam os animais.</p>
    <p>
      <bold>M&#233;todo estat&#237;stico</bold>
    </p>
    <p>As compara&#231;&#245;es foram feitas pela ANOVA de uma via, complementadas pelo teste de Tukey, quando os dados apresentaram distribui&#231;&#227;o normal. Quando os dados n&#227;o apresentaram distribui&#231;&#227;o normal, as compara&#231;&#245;es entre os grupos foram feitas pelo teste de Kruskal-Wallis. Os dados foram expressos em m&#233;dia &#177; desvio padr&#227;o (para distribui&#231;&#227;o normal) ou mediana com os percentis 25 e 75 (para distribui&#231;&#227;o n&#227;o normal). O n&#237;vel de signific&#226;ncia foi 5%. As an&#225;lises estat&#237;sticas foram feitas com o programa SigmaStat for Windows v3.5 (SPSS Inc, Chicago, IL).</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Em rela&#231;&#227;o &#224; frequ&#234;ncia card&#237;aca, os animais do Grupo BB apresentaram menores valores em rela&#231;&#227;o aos animais fumantes (C = 358 &#177; 74 bpm, F = 374 &#177; 53 bpm, BB = 297 &#177; 30 bpm; P = 0,02). Por outro lado, n&#227;o observamos diferen&#231;a significativa na PAS caudal entre os animais dos tr&#234;s grupos (C = 117 (110-120) mmHg, F = 127 (110-140) mmHg, BB = 117 (115-120) mmHg; P = 0,142). </p>
    <p>Os dados do estudo ecocardiogr&#225;fico est&#227;o na <xref ref-type="table" rid="tab01">Tabela 1</xref>. As an&#225;lises morfol&#243;gicas mostraram que os animais do Grupo F apresentaram maiores di&#226;metros diast&#243;licos do ventr&#237;culo esquerdo (VE), ajustados ao peso corporal (PC), em rela&#231;&#227;o aos animais controle (C = 18,6 &#177; 3,4 mm/kg, F = 22,8 &#177; 1,8 mm/kg, BB = 21,7 &#177; 1,8 mm/kg; P = 0,003). Por outro lado, o grupo BB apresentou valores intermedi&#225;rios dessa vari&#225;vel, j&#225; que n&#227;o houve diferen&#231;a em compara&#231;&#227;o aos valores tanto de C como de F. </p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-92-06-0479-00011-gt01.jpg"/></table-wrap>
    <p>A an&#225;lise funcional mostrou que os animais do Grupo F apresentaram maiores di&#226;metros sist&#243;licos do ventr&#237;culo esquerdo, ajustado ao PC (C = 8,6 &#177; 2,1 mm/kg, F = 11,3 &#177; 1,3 mm/kg, BB = 9,9 &#177; 1,2 mm/kg; P = 0,004) em rela&#231;&#227;o aos animais controle. Novamente, o Grupo BB apresentou valores intermedi&#225;rios dessa vari&#225;vel, j&#225; que n&#227;o houve diferen&#231;a em compara&#231;&#227;o aos valores tanto de C como de F. Do mesmo modo, houve tend&#234;ncia de menor fra&#231;&#227;o de eje&#231;&#227;o (C = 0,90 &#177; 0,03 %, F = 0,87 &#177; 0,03 %, BB =0,90 &#177; 0,02 %; P = 0,07) no Grupo F em compara&#231;&#227;o com C e tend&#234;ncia de menor porcentagem de encurtamento (C = 54 &#177; 5, F = 50 &#177; 4, BB = 54 &#177; 4; P = 0,09) no Grupo F, que os animais dos Grupos C e BB. N&#227;o foram encontradas diferen&#231;as em rela&#231;&#227;o &#224;s outras vari&#225;veis.</p>
    <p>Em rela&#231;&#227;o &#224;s vari&#225;veis morfom&#233;tricas card&#237;acas (<xref ref-type="table" rid="tab02">Tabela 2</xref>), os animais do grupo BB apresentaram tend&#234;ncia de menores valores do peso do VE ajustado pelo peso do corpo dos animais (VE/PC), em rela&#231;&#227;o aos animais fumantes (C = 1,94 (1,87 &#150; 1,97) mg/g, F = 2,03 (1,9-2,1) mg/g, BB = 1,89 (1,86-1,94) mg/g; P = 0,09). N&#227;o foram encontradas diferen&#231;as em rela&#231;&#227;o &#224;s outras vari&#225;veis.</p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-92-06-0479-00011-gt02.jpg"/></table-wrap>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>O objetivo desse estudo foi analisar o efeito da administra&#231;&#227;o de beta-bloqueador no processo de remodela&#231;&#227;o ventricular, induzido pela exposi&#231;&#227;o &#224; fuma&#231;a de cigarro em ratos. Os resultados mostraram que o bloqueio dos receptores adren&#233;rgicos beta foi acompanhado por atenua&#231;&#227;o de algumas altera&#231;&#245;es morfol&#243;gicas e funcionais causadas pelo tabagismo. </p>
    <p>Altera&#231;&#245;es da geometria, volume, massa e constitui&#231;&#227;o do cora&#231;&#227;o, em resposta &#224; agress&#227;o mioc&#225;rdica ou &#224;s altera&#231;&#245;es nas condi&#231;&#245;es da carga, t&#234;m sido estudadas com o nome de remodela&#231;&#227;o card&#237;aca<sup>1-3</sup>. Aceita-se que a hipertrofia e o aumento da cavidade desempenham papel importante no processo de remodela&#231;&#227;o. Nossos dados confirmam estudos pr&#233;vios<sup>4-9</sup> em que o tabagismo foi acompanhado por aumento da cavidade ventricular no modelo do rato. Adicionalmente, um dos achados importantes do presente estudo foi que a administra&#231;&#227;o de propranolol, um beta-bloqueador n&#227;o seletivo (com a&#231;&#227;o em receptores &#946;1 e &#946;2) resultou em valores intermedi&#225;rios do di&#226;metro dist&#243;lico do VE, em compara&#231;&#227;o aos animais fumantes e controles. Inicialmente, n&#227;o foram encontradas diferen&#231;as entre os animais BB e os fumantes. No entanto, os valores de BB tamb&#233;m n&#227;o foram diferentes dos animais controle. Assim, nossos dados permitem sugerir que o propranolol n&#227;o preveniu, mas atenuou o aumento da cavidade induzido pelo tabagismo. </p>
    <p>Outro aspecto relevante refere-se ao fato de que, classicamente, o processo de remodela&#231;&#227;o est&#225; associado com diferentes graus de disfun&#231;&#227;o ventricular. Inicialmente, as altera&#231;&#245;es morfol&#243;gicas caracter&#237;sticas da remodela&#231;&#227;o podem ser consideradas como adaptativas frente &#224;s novas condi&#231;&#245;es de carga a que o cora&#231;&#227;o agredido &#233; submetido. Entretanto, cronicamente, podem ocorrer altera&#231;&#245;es gen&#233;ticas, moleculares e celulares card&#237;acas que s&#227;o capazes de levar &#224; piora progressiva da fun&#231;&#227;o ventricular<sup>1-3</sup>. Nossos dados est&#227;o em conson&#226;ncia com esse conceito, j&#225; que o aumento do di&#226;metro diast&#243;lico do VE com o tabagismo foi acompanhado por piora de &#237;ndices da fun&#231;&#227;o ventricular esquerda, como o di&#226;metro sist&#243;lico final, fra&#231;&#227;o de eje&#231;&#227;o e porcentagem de encurtamento do VE. Aspecto a ser considerado, refere-se ao fato de que o propranolol resultou em valores intermed&#225;rios entre os animais fumantes e os animais controle. Assim, podemos inferir que a administra&#231;&#227;o de beta-bloqueador n&#227;o preveniu, mas atenuou as altera&#231;&#245;es funcionais induzidas pelo tabagismo. Esse efeito &#233; ainda mais relevante tendo-se em vista que os animais tratados com propranolol apresentavam menor frequ&#234;ncia card&#237;aca. Fisiologicamente, a redu&#231;&#227;o da frequ&#234;ncia card&#237;aca est&#225; associada com diminui&#231;&#227;o dos valores dos &#237;ndices de eje&#231;&#227;o ventricular, independente de varia&#231;&#245;es do estado contr&#225;til do mioc&#225;rdio.</p>
    <p>Os mecanismos respons&#225;veis pelas altera&#231;&#245;es morfol&#243;gicas e funcionais card&#237;acas, induzidas pela exposi&#231;&#227;o &#224; fuma&#231;a do cigarro n&#227;o est&#227;o completamente esclarecidos. Existem evid&#234;ncias suficientes mostrando que o mon&#243;xido de carbono est&#225; associado com apoptose, disfun&#231;&#227;o card&#237;aca, hipertrofia e dilata&#231;&#227;o da c&#226;mara ventricular esquerda ap&#243;s o infarto experimental<sup>18,19</sup>. Trabalho anterior no modelo de rato mostrou que a administra&#231;&#227;o de antioxidante atenuou a remodela&#231;&#227;o induzida pelo tabagismo, sugerindo que o estresse oxidativo tem participa&#231;&#227;o fisiopatol&#243;gica nas altera&#231;&#245;es card&#237;acas provocadas pelo fumo<sup>6</sup>. De outra maneira, estudos pr&#233;vios, com per&#237;odos de observa&#231;&#227;o maiores que o do presente trabalho (quatro e seis meses), n&#227;o observaram altera&#231;&#245;es no PO<sub>2</sub> e na porcentagem de satura&#231;&#227;o da hemoglobina pelo O<sub>2</sub><sup>5,9</sup>. Assim, hipoxemia cr&#244;nica e altera&#231;&#245;es na viscosidade sangu&#237;nea secund&#225;rias a hip&#243;xia, potenciais candidatos que poderiam explicar os resultados de nosso estudo, provavelmente n&#227;o tem participa&#231;&#227;o na fisiopatologia das altera&#231;&#245;es induzidas pelo cigarro. Do mesmo modo, n&#227;o foi encontrada associa&#231;&#227;o entre a remodela&#231;&#227;o card&#237;aca induzida pelo tabagismo e a ativa&#231;&#227;o de metaloproteinases dois e nove<sup>8</sup>. Outro mecanismo potencial est&#225; associado ao fato de que dados anteriores mostraram que a administra&#231;&#227;o de nicotina em ratos conscientes resultou em vasoconstri&#231;&#227;o. Assim, a simpatectomia aboliu os efeitos vasoativos da nicotina<sup>20</sup>. No mesmo modelo, a fuma&#231;a de cigarro causou eleva&#231;&#227;o dos n&#237;veis de endotelina-1<sup>21</sup> e a administra&#231;&#227;o de antagonista seletivo dos receptores A da endotelina atenuaram a resposta press&#243;rica induzida pela nicotina<sup>22</sup>. Em outro estudo, a administra&#231;&#227;o de nicotina diminuiu a s&#237;ntese de prostaciclina pelo endot&#233;lio vascular<sup>23</sup>. Adicionalmente, a administra&#231;&#227;o de antagonista da vasopressina atenuou a vasoconstri&#231;&#227;o induzida pela nicotina nos vasos sangu&#237;neos da pele<sup>24</sup>. Em nosso trabalho, entretanto, os animais expostos &#224; fuma&#231;a do cigarro e tratados com propranolol n&#227;o apresentaram diferen&#231;as nos n&#237;veis de press&#227;o arterial em rela&#231;&#227;o aos animais n&#227;o tratados. Dessa forma, nossos dados sugerem que a atenua&#231;&#227;o da remodela&#231;&#227;o causada pelo propranolol n&#227;o foi resultado dos efeitos da medica&#231;&#227;o na press&#227;o arterial.</p>
    <p>Devemos considerar que a ativa&#231;&#227;o neurohumoral poderia, por mecanismos aut&#243;crinos e par&#225;crinos, resultar em altera&#231;&#245;es em vias sinalizadoras intracelulares<sup>12,25</sup>. A cl&#225;ssica subdivis&#227;o de receptores &#946;-adren&#233;rgicos estabelece tr&#234;s subtipos: &#946;1, &#946;2 e &#946;3 que ativam a adenil ciclase, por meio da prote&#237;na G, aumentando os n&#237;veis de AMP c&#237;clico, com posterior est&#237;mulo da prote&#237;na quinase A. Essa, por sua vez, causa a fosforila&#231;&#227;o de diversas prote&#237;nas que modulam a contratilidade (por exemplo: canais L de c&#225;lcio, fosfolamban, troponina I, receptores de rianodina, SERCA2a) e a remodela&#231;&#227;o card&#237;aca (fosfatidil inositol 3-quinase, fatores de crescimento, ERK, quinases ativadas por mit&#243;genos, entre outros). Assim, o bloqueio de receptores &#946;-adren&#233;rgicos est&#225; associado com menor remodela&#231;&#227;o secund&#225;ria a v&#225;rios est&#237;mulos, tanto em estudos experimentais como cl&#237;nicos<sup>12,25</sup>. Nossos dados est&#227;o em concord&#226;ncia com essas evid&#234;ncias, j&#225; que houve atenua&#231;&#227;o da remodela&#231;&#227;o induzida pela exposi&#231;&#227;o &#224; fuma&#231;a do cigarro. Considerando que n&#227;o houve diferen&#231;a nos n&#237;veis press&#243;ricos entre os animais dos tr&#234;s grupos, nossos dados sugerem que a atenua&#231;&#227;o da remodela&#231;&#227;o causada pelo propranolol provavelmente envolveu vias de sinaliza&#231;&#227;o intracelulares moduladas pelos receptores &#946;-adren&#233;rgicos, mas que provavelmente n&#227;o foram em decorr&#234;ncia de efeitos hemodin&#226;micos. </p>
    <p>Um aspecto relevante do presente trabalho refere-se &#224;s implica&#231;&#245;es cl&#237;nicas dos nossos resultados. Existem evid&#234;ncias de que o tabagismo pode resultar em altera&#231;&#245;es morfol&#243;gicas e funcionais card&#237;acas em humanos. Por exemplo, no estudo observacional CARDIA, fumantes tiveram maior massa ventricular esquerda, em compara&#231;&#227;o com n&#227;o fumantes, avaliados por ecocardiograma<sup>26</sup>. Adicionalmente, a inala&#231;&#227;o aguda da fuma&#231;a de cigarro foi acompanhada por dist&#250;rbios da fun&#231;&#227;o diast&#243;lica, em pacientes com documentada doen&#231;a arterial coronariana<sup>27,28</sup>. Desse modo, existe a possibilidade de que a administra&#231;&#227;o de beta-bloqueador possa interferir com as altera&#231;&#245;es induzidas pelo tabagismo tamb&#233;m em humanos.</p>
    <p>Finalmente, nossos resultados devem ser analisados considerando-se potenciais limita&#231;&#245;es. Em primeiro lugar, as vari&#225;veis analisadas foram apenas par&#226;metros ecocardiogr&#225;ficos e de peso. Nosso trabalho n&#227;o avaliou outras vari&#225;veis envolvidas no processo de remodela&#231;&#227;o como, por exemplo, conte&#250;do de col&#225;geno intersticial. Outro aspecto &#233; que apenas algumas das vari&#225;veis analisadas foram estatisticamente diferentes. Esse fato se deu, provavelmente, em decorr&#234;ncia do pequeno n&#250;mero de nossa amostra. Entretanto, apesar dessas limita&#231;&#245;es, acreditamos que as vari&#225;veis analisadas foram suficientes para caracterizar o processo de remodela&#231;&#227;o induzido pelo tabagismo e mostrar efeitos biol&#243;gicos com o propranolol. </p>
    <p>Em conclus&#227;o, a administra&#231;&#227;o de propranolol n&#227;o preveniu, mas atenuou algumas das vari&#225;veis da remodela&#231;&#227;o ventricular induzida pela exposi&#231;&#227;o &#224; fuma&#231;a do cigarro em ratos.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Leonardo Ant&#244;nio Mamede Zornoff </p>
        <p> Faculdade de Medicina de Botucatu, Departamento de Cl&#237;nica M&#233;dica, Rubi&#227;o Jr </p>
        <p> 18.618-000, Botucatu, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="lzornoff@fmb.unesp.br">lzornoff@fmb.unesp.br</email>, </p>
        <p>
          <email xlink:href="lzornoff@cardiol.br">lzornoff@cardiol.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 05/03/2008; revisado recebido em 29/05/2008; aceito em 09/07/2008.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Francis GS. Pathophysiology of chronic heart    failure. Am J Med. 2001; 110: 37S-46S.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pathophysiology of chronic heart failure</article-title>
          <source>Am J Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>37S</fpage>
          <lpage>46S</lpage>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Francis</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Pfeffer MA, Braunwald E. Ventricular remodeling    after myocardial infarction: experimental observations and clinical implications.    Circulation. 1990; 81: 1161-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ventricular remodeling after myocardial infarction: experimental observations and clinical implications</article-title>
          <source>Circulation</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>1161</fpage>
          <lpage>72</lpage>
          <volume>81</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts    and clinical implications: a consensus paper from an international forum on    cardiac remodeling. J Am Coll Cardiol. 2000; 35: 569-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>569</fpage>
          <lpage>82</lpage>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cohn</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sharpe</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Paiva SAR, Zornoff LAM, Okoshi MP, Okoshi    K, Cicogna AC, Campana AO. Behavior of cardiac variables in animals exposed    to cigarette smoke. Arq Bras Cardiol. 2003; 81: 221-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Behavior of cardiac variables in animals exposed to cigarette smoke</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>221</fpage>
          <lpage>8</lpage>
          <volume>81</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Paiva</surname>
              <given-names>SAR</given-names>
            </name>
            <name>
              <surname>Zornoff</surname>
              <given-names>LAM</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cicogna</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Campana</surname>
              <given-names>AO</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Castardeli E, Paiva SAR, Matsubara BB, Matsubara    L S, Minicucci MF, AzevedoPS, et al. Chronic cigarette smoke exposure results    in cardiac remodeling and impaired ventricular function in rats. Arq Bras Cardiol.    2005; 84: 320-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chronic cigarette smoke exposure results in cardiac remodeling and impaired ventricular function in rats</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>320</fpage>
          <lpage>4</lpage>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Castardeli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Paiva</surname>
              <given-names>SAR</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>L S</given-names>
            </name>
            <name>
              <surname>Minicucci</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Zornoff LAM, Matsubara LS, Matsubara BB, Okoshi    MP, Okoshi K, Dal Pai-Silva, et al. Beta-carotene supplementation attenuates    cardiac remodelling induced by one-month tobacco-exposure in rats. Tox Sci.    2006; 90: 259-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Beta-carotene supplementation attenuates cardiac remodelling induced by one-month tobacco-exposure in rats</article-title>
          <source>Tox Sci</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>259</fpage>
          <lpage>66</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zornoff</surname>
              <given-names>LAM</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dal</surname>
              <given-names>Pai-Silva</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Zornoff LAM, Matsubara BB, Matsubara LS, Minicucci    MF, Azevedo PS, Campana AO, et al. Cigarette smoke exposure intensifies ventricular    remodeling process following myocardial infarction. Arq Bras Cardiol. 2006;    86: 276-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cigarette smoke exposure intensifies ventricular remodeling process following myocardial infarction</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>276</fpage>
          <lpage>82</lpage>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zornoff</surname>
              <given-names>LAM</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Minicucci</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Campana</surname>
              <given-names>AO</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Castardeli E, Duarte DR, Minicucci MF, Azevedo    PS, Matsubara BB, Matsubara LS, et al. Tobacco smoke-induced left ventricular    remodelling is not associated with metalloproteinase-2 or -9 activation. Eur    J Heart Fail. 2007; 9: 1081-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Tobacco smoke-induced left ventricular remodelling is not associated with metalloproteinase-2 or -9 activation</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1081</fpage>
          <lpage>5</lpage>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Castardeli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Duarte</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Minicucci</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Castardeli E, Duarte DR, Minicucci MF, Azevedo    PS, Matsubara BB, Matsubara LS, et al. Exposure time and ventricular remodeling    induced by tobacco smoke exposure in rats. Med Sci Monit. 2008; 14 (3): BR62-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exposure time and ventricular remodeling induced by tobacco smoke exposure in rats</article-title>
          <source>Med Sci Monit</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>BR62</fpage>
          <lpage>66</lpage>
          <issue>3</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Castardeli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Duarte</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Minicucci</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Plante E, Lachance D, Champetier S, Drolet    MC, Roussel E, Arsenault M, et al. Benefits of long-term beta-blockade in experimental    chronic aortic regurgitation. Am J Physiol Heart Circ Physiol. 2008; 294 (4):    H1888-95.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Benefits of long-term beta-blockade in experimental chronic aortic regurgitation</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>H1888</fpage>
          <lpage>95</lpage>
          <issue>4</issue>
          <volume>294</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Plante</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lachance</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Champetier</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Drolet</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Roussel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Arsenault</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Malfato G, Branzi G, Ciambelotti F, Valli    P, Bizzi C, Fachini M. Different ventricular remodelling and autonomic modulation    after long-term beta-blocker treatment in hypertensive, ischaemic and idiopathic    dilated cardiomyopathy. J Cardiovasc Med. 2007; 8: 840-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Different ventricular remodelling and autonomic modulation after long-term beta-blocker treatment in hypertensive, ischaemic and idiopathic dilated cardiomyopathy</article-title>
          <source>J Cardiovasc Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>840</fpage>
          <lpage>5</lpage>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Malfato</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Branzi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ciambelotti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Valli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bizzi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fachini</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Perrino C, Rockman HA. Reversal of cardiac    remodeling by modulation of adrenergic receptors: a new frontier in heart failure.    Curr Opin Cardiol. 2007; 22: 443-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure</article-title>
          <source>Curr Opin Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>443</fpage>
          <lpage>9</lpage>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Perrino</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rockman</surname>
              <given-names>HA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Yaoita H, Sakabe H, Maehara K, Maruyama Y.    Different effects of carvedilol, metoprolol, and propranolol on left ventricular    remodeling after coronary stenosis or after permanent coronary occlusion in    rats. Circulation. 2002; 105: 975-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>975</fpage>
          <lpage>80</lpage>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yaoita</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sakabe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Maehara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Wang XD, Liu C, Bronson RT, Smith DE, Krinsky    NI, Russell M. Retinoid signaling and activator protein-1 expression in ferrets    given beta-carotene supplements and exposed to tobacco smoke. J Natl Cancer    Inst. 1999; 91: 60-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke</article-title>
          <source>J Natl Cancer Inst</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>60</fpage>
          <lpage>6</lpage>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>XD</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bronson</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Krinsky</surname>
              <given-names>NI</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Sahn DJ, DeMaria A, Kisslo J, Weyman AE.    The Committee on M-Mode Standardization of the American Society of Echocardiography,    Recommendations regarding quantitation in M-mode echocardiography: results of    a survey of echocardiographic measurements. Circulation. 1978; 58: 1072-83.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Committee on M-Mode Standardization of the American Society of Echocardiography, Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements</article-title>
          <source>Circulation</source>
          <date>
            <year>1978</year>
          </date>
          <fpage>1072</fpage>
          <lpage>83</lpage>
          <volume>58</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sahn</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>DeMaria</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kisslo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weyman</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Zornoff LA, Paiva SA, Matsubara BB, Matsubara    LS, Spadaro J. Combination therapy with angiotensin converting enzyme inhibition    and AT1 receptor inhibitor on ventricular remodeling after myocardial infarction    in rats. J Cardiovasc Pharmacol Ther. 2000; 5: 203-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor on ventricular remodeling after myocardial infarction in rats</article-title>
          <source>J Cardiovasc Pharmacol Ther</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>203</fpage>
          <lpage>9</lpage>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zornoff</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Paiva</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Spadaro</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Matsubara LS, Matsubara BB, Okoshi MP, Cicogna    AC, Janicki JS. Alterations in myocardial collagen content affect rat papillary    muscle function. Am J Physiol Heart Circ Physiol. 2000; 279: H1534-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Alterations in myocardial collagen content affect rat papillary muscle function</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>H1534</fpage>
          <lpage>9</lpage>
          <volume>279</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Cicogna</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Janicki</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Durante W, Johnson FK, Johnson RA. Role of    carbon monoxide in cardiovascular function. J Cell Mol Med. 2006; 10: 672-86.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of carbon monoxide in cardiovascular function</article-title>
          <source>J Cell Mol Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>672</fpage>
          <lpage>86</lpage>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Durante</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. S&#248;rhaug S, Steinshamn S, Nilsen OG,    Waldum HL. Chronic inhalation of carbon monoxide: effects on the respiratory    and cardiovascular system at doses corresponding to tobacco smoking. Toxicology.    2006; 228: 280-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chronic inhalation of carbon monoxide: effects on the respiratory and cardiovascular system at doses corresponding to tobacco smoking</article-title>
          <source>Toxicology</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>280</fpage>
          <lpage>90</lpage>
          <volume>228</volume>
          <person-group person-group-type="author">
            <name>
              <surname>S&#248;rhaug</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Steinshamn</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nilsen</surname>
              <given-names>OG</given-names>
            </name>
            <name>
              <surname>Waldum</surname>
              <given-names>HL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Marano G, Ramirez A, Mori I, Ferrari AU.    Sympathectomy inhibits the vasoactive effects of nicotine in concious rats.    Cardiovasc Res. 1999; 42: 201-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sympathectomy inhibits the vasoactive effects of nicotine in concious rats</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>201</fpage>
          <lpage>5</lpage>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Marano</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>AU</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Haak T, Jungmann E, Raab C, Usadel KH. Elevated    endothelin-1 levels after cigarette smoking. Metabolism. 1994; 43: 267-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Elevated endothelin-1 levels after cigarette smoking</article-title>
          <source>Metabolism</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>267</fpage>
          <lpage>9</lpage>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Haak</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jungmann</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Raab</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Usadel</surname>
              <given-names>KH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Tanus-Santos JE, Sampaio RC, Hyslop S, Franchini    KG, Moreno Jr H. Endothelin ETA receptor antagonism attenuates the pressor effects    of nicotine in rats. Eur J Pharmacol. 2000; 396: 33-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endothelin ETA receptor antagonism attenuates the pressor effects of nicotine in rats</article-title>
          <source>Eur J Pharmacol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>33</fpage>
          <lpage>7</lpage>
          <volume>396</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tanus-Santos</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Sampaio</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Hyslop</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Franchini</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Moreno Jr</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Klein LW. Cigarette smoking, atherosclerosis    and the coronary hemodynamic response: a unifying hypothesis. J Am Coll Cardiol.    1984; 4: 972-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cigarette smoking, atherosclerosis and the coronary hemodynamic response: a unifying hypothesis</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1984</year>
          </date>
          <fpage>972</fpage>
          <lpage>4</lpage>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Klein</surname>
              <given-names>LW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Khosla S, Laddu A, Ehrenpreis S, Somberg    JC. Cardiovascular effects of nicotine: relation to deleterious effects of cigarette    smoking. Am Heart J. 1994; 127: 1669-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular effects of nicotine: relation to deleterious effects of cigarette smoking</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>1669</fpage>
          <lpage>72</lpage>
          <volume>127</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Khosla</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Laddu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ehrenpreis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Somberg</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Lohse MJ, Engelhardt S, Eschenhagen T. What    is the role of &#946;-adrernegic    signaling in heart failure? Circ Res. 2003; 93: 896-906.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>What is the role of &#223;-adrernegic signaling in heart failure?</article-title>
          <source>Circ Res</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>896</fpage>
          <lpage>906</lpage>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lohse</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Engelhardt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Eschenhagen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Gidding SS, Xie X, Liu K, Manolio T, Flack    JM, Gardin JM. Cardiac function in smokers and nonsmokers: the CARDIA study.    The Coronary Artery Risk Development in Yong Adults Study. J Am Coll Cardiol.    1995; 26: 211-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac function in smokers and nonsmokers: the CARDIA study. The Coronary Artery Risk Development in Yong Adults Study</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>211</fpage>
          <lpage>6</lpage>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gidding</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Manolio</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Flack</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Gardin</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Kyriakides ZS, Kremastinos DT, Rentoukas    E, Mavrogheni S, Kremastinos DI, Toutouzas P. Acute effects of cigarette smoking    on left ventricular diastolic function. Eur Heart J. 1992; 13: 743-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Acute effects of cigarette smoking on left ventricular diastolic function</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>743</fpage>
          <lpage>8</lpage>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kyriakides</surname>
              <given-names>ZS</given-names>
            </name>
            <name>
              <surname>Kremastinos</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Rentoukas</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mavrogheni</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kremastinos</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Toutouzas</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Stork T, Eichstadt H, Mockel M, Bortfeldt    R, Muller R, Hochrein H. Changes of diastolic function induced by cigarette    smoking: an echocardiographic study in patients with coronary artery disease.    Clin Cardiol. 1992; 15: 80-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Changes of diastolic function induced by cigarette smoking: an echocardiographic study in patients with coronary artery disease</article-title>
          <source>Clin Cardiol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>80</fpage>
          <lpage>6</lpage>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stork</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Eichstadt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mockel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bortfeldt</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hochrein</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Efectos de la administraci&#243;n de betabloqueante en la remodelaci&#243;n ventricular inducida por el tabaquismo en ratas</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: A&#250;n se desconoce el rol del sistema adren&#233;rgico en la remodelaci&#243;n inducida por el tabaquismo. OBJETIVO: Investigar la influencia del propranolol en la remodelaci&#243;n inducida por la exposici&#243;n al humo del cigarrillo. M&#201;TODOS: Se dividieron las ratas en tres grupos: 1) C, n=10 - animales control; 2) F, n=10 - animales expuestos al humo de cigarrillo; 3) BB, n=10 - animales expuestos al humo de cigarrillo y que recibieron propranolol (40 mg/kg/d&#237;a). Tras dos meses, los animales fueron sometidos a estudio ecocardiogr&#225;fico y morfom&#233;trico. Se emple&#243; el an&#225;lisis de varianza (ANOVA) de una v&#237;a (promedio &#177; desviaci&#243;n est&#225;ndar) o Kruskal-Wallis (mediana e intervalo intercuartil). RESULTADOS: El Grupo BB present&#243; menor frecuencia cardiaca que el Grupo F (C = 358 &#177; 74 lpm, F = 374 &#177; 53 lpm, BB = 297 &#177; 30; P = 0,02). El Grupo F present&#243; mayores di&#225;metros diast&#243;licos (C = 18,6 &#177; 3,4 mm/kg, F = 22,8 &#177; 1,8 mm/kg, BB = 21,7 &#177; 1,8 mm/kg; P = 0,003) y sist&#243;licos (C = 8,6 &#177; 2,1 mm/kg, F = 11,3 &#177; 1,3 mm/kg, BB = 9,9 &#177; 1,2 mm/kg; P = 0,004) del ventr&#237;culo izquierdo (VI), ajustado al peso corporal (PC) y tendencia de menor fracci&#243;n de eyecci&#243;n (C = 0,90 &#177; 0,03, F = 0,87 &#177; 0,03, BB =0,90 &#177; 0,02; P = 0,07) que el Grupo C. El Grupo BB present&#243; tendencia de menor relaci&#243;n VI/PC que el Grupo F (C = 1,94 (1,87 - 1,97), F = 2,03 (1,9-2,1) mg/g, BB = 1,89 (1,86-1,94); P = 0,09). CONCLUSI&#211;N: La administraci&#243;n de propranolol atenu&#243; algunas variables de la remodelaci&#243;n ventricular inducida por la exposici&#243;n al humo del cigarrillo en ratas.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Beta-antagonistas adrenergicos</kwd>
        <kwd>remodelaci&#243;n/remodelamiento ventricular</kwd>
        <kwd>tabaquismo</kwd>
        <kwd>ratas</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="tx-body2"/>Efectos de la administraci&#243;n de betabloqueante en la remodelaci&#243;n ventricular inducida por el tabaquismo en ratas</p>
      <p>
        <bold>Daniella R. Duarte; Lucienne C. Oliveira; Marcos F. Minicucci; Paula S. Azevedo; Beatriz B. Matsubara; Luiz S. Matsubara; &#193;lvaro O. Campana; Sergio A. R. Paiva; Leonardo A. M. Zornoff</bold>
      </p>
      <p> Faculdade de Medicina de Botucatu, Botucatu, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> A&#250;n se desconoce el rol del sistema adren&#233;rgico en la remodelaci&#243;n inducida por el tabaquismo.</p>
      <p><bold>OBJETIVO:</bold> Investigar la influencia del propranolol en la remodelaci&#243;n inducida por la exposici&#243;n al humo del cigarrillo.</p>
      <p><bold>M&#201;TODOS:</bold> Se dividieron las ratas en tres grupos: 1) C, n=10 - animales control; 2) F, n=10 - animales expuestos al humo de cigarrillo; 3) BB, n=10 - animales expuestos al humo de cigarrillo y que recibieron propranolol (40 mg/kg/d&#237;a). Tras dos meses, los animales fueron sometidos a estudio ecocardiogr&#225;fico y morfom&#233;trico. Se emple&#243; el an&#225;lisis de varianza (ANOVA) de una v&#237;a (promedio &#177; desviaci&#243;n est&#225;ndar) o Kruskal-Wallis (mediana e intervalo intercuartil).</p>
      <p><bold>RESULTADOS:</bold> El Grupo BB present&#243; menor frecuencia cardiaca que el Grupo F (C = 358 &#177; 74 lpm, F = 374 &#177; 53 lpm, BB = 297 &#177; 30; P = 0,02). El Grupo F present&#243; mayores di&#225;metros diast&#243;licos (C = 18,6 &#177; 3,4 mm/kg, F = 22,8 &#177; 1,8 mm/kg, BB = 21,7 &#177; 1,8 mm/kg; P = 0,003) y sist&#243;licos (C = 8,6 &#177; 2,1 mm/kg, F = 11,3 &#177; 1,3 mm/kg, BB = 9,9 &#177; 1,2 mm/kg; P = 0,004) del ventr&#237;culo izquierdo (VI), ajustado al peso corporal (PC) y tendencia de menor fracci&#243;n de eyecci&#243;n (C = 0,90 &#177; 0,03, F = 0,87 &#177; 0,03, BB =0,90 &#177; 0,02; P = 0,07) que el Grupo C. El Grupo BB present&#243; tendencia de menor relaci&#243;n VI/PC que el Grupo F (C = 1,94 (1,87 - 1,97), F = 2,03 (1,9-2,1) mg/g, BB = 1,89 (1,86-1,94); P = 0,09).</p>
      <p><bold>CONCLUSI&#211;N:</bold> La administraci&#243;n de propranolol atenu&#243; algunas variables de la remodelaci&#243;n ventricular inducida por la exposici&#243;n al humo del cigarrillo en ratas. (Arq Bras Cardiol 2009;92(6):462-466)</p>
      <p><bold>Palabras clave:</bold> Beta-antagonistas adrenergicos/administraci&#243;n y dosificaci&#243;n, remodelaci&#243;n/remodelamiento ventricular, tabaquismo, ratas.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Se puede definir la remodelaci&#243;n cardiaca como variaciones en el tama&#241;o, masa, geometr&#237;a, composici&#243;n y funci&#243;n del coraz&#243;n. Ese proceso ocurre en respuesta a diversos est&#237;mulos, incluso infarto de miocardio, hipertensi&#243;n arterial sist&#233;mica, enfermedad valvular y mutaciones gen&#233;ticas<sup>1-3</sup>. Inicialmente, la remodelaci&#243;n es el proceso adaptativo compensatorio, desde que las alteraciones morfol&#243;gicas puedan restaurar o preservar la funci&#243;n cardiaca en respuesta a diferentes agresiones. Cr&#243;nicamente, sin embargo, el proceso de remodelaci&#243;n resulta en ca&#237;da progresiva de la funci&#243;n ventricular, se&#241;ales y s&#237;ntomas de insuficiencia cardiaca y muerte<sup>1-3</sup>.</p>
      <p>Recientemente, diversos estudios mostraron que, en el modelo de rata, la exposici&#243;n al humo del cigarrillo resulta en remodelaci&#243;n cardiaca, caracterizada por aumento de la cavidad ventricular izquierda, hipertrofia de los miocitos y descenso de la funci&#243;n ventricular<sup>4-9</sup>. Sin embargo, por ser determinados, los mecanismos implicados en ese fen&#243;meno todav&#237;a permanecen. Entre los mecanismos implicados en la modulaci&#243;n de las alteraciones funcionales y morfol&#243;gicas presentes en diferentes modelos de agresi&#243;n, la activaci&#243;n del sistema adren&#233;rgico parece desempe&#241;ar un rol destacado<sup>10,11</sup>. De esa manera, los estudios ya mostraron que el empleo de betabloqueantes aten&#250;a la remodelaci&#243;n cardiaca en diferentes modelos experimentales y cl&#237;nicos<sup>12</sup>. Sin embargo, los efectos de la administraci&#243;n de betabloqueantes en la remodelaci&#243;n inducida por la exposici&#243;n al humo del cigarrillo no se conocen a&#250;n.</p>
      <p>Por lo tanto, este estudio tuvo por objeto investigar la influencia de la administraci&#243;n de propranolol en la remodelaci&#243;n ventricular inducida por la exposici&#243;n al humo de cigarrillo en ratas.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>La Comisi&#243;n de &#201;tica en Experimentaci&#243;n Animal de la Facultad de Medicina de Botucatu aprob&#243; el protocolo experimental del presente trabajo, en conformidad con los Principios &#201;ticos en la Experimentaci&#243;n Animal, adoptados por el Colegio Brasile&#241;o de Experimentaci&#243;n Animal.</p>
      <p>
        <bold>Protocolo y grupos experimentales</bold>
      </p>
      <p>Se dividieron a las ratas Wistar, machos, pesando entre 200g y 230g, en tres grupos experimentales:</p>
      <p>1) Grupo C, n=10 - conformado por animales no expuestos al humo del cigarrillo;</p>
      <p>2) Grupo F, n=10 - conformado por los animales expuestos al humo de cigarrillo por per&#237;odo de dos meses;</p>
      <p>3) Grupo BB, n=10 - conformado por los animales expuestos al humo de cigarrillo por per&#237;odo de dos meses y que recibieron propranolol (40 mg/kg/d&#237;a) disuelto en el agua de beber. Estudio previo evidenci&#243; que esa dosis posee efectos biol&#243;gicos en el modelo de la rata<sup>13</sup>. Como la medicaci&#243;n estaba diluida en agua, se realiz&#243; el control diario de la ingesti&#243;n de raci&#243;n y agua por los animales. </p>
      <p>
        <bold>La exposici&#243;n al humo</bold>
      </p>
      <p>Para exponerse a los animales al humo del cigarrillo, se utiliz&#243; el m&#233;todo propuesto por Wang et al<sup>14</sup>, ya estandarizado en nuestro laborat&#243;rio<sup>4-9</sup>. Al fin del per&#237;odo de estudio experimental, los animales fueron expuestos al humo de 40 cigarrillos/d&#237;a. Con esa metodolog&#237;a, la exposici&#243;n al humo del cigarrillo resulta en remodelaci&#243;n cardiaca y empeoramiento funcional<sup>4-9</sup>.</p>
      <p>
        <bold>Presi&#243;n sist&#243;lica de la cola</bold>
      </p>
      <p>La medici&#243;n de la presi&#243;n arterial sist&#243;lica (PAS) de la cola se llev&#243; a cabo en dos semanas antes del sacrificio. Los animales fumadores no fueron sometidos a la exposici&#243;n al humo del cigarrillo por per&#237;odo de 24 horas antes de la toma de los valores. Se emple&#243; el plestim&#243;grafo de cola, constituido por un pol&#237;grafo (Byo-Sistem PE 300, NARCO) con sensor colocado en la regi&#243;n proximal de la cola y un esfigmoman&#243;metro electr&#243;nico, posibilitando as&#237; el registro gr&#225;fico de la presi&#243;n arterial. Se calentaron a los animales en caja de madera a 37&#186;C, con el calor generado por dos l&#225;mparas de filamentos, por 4 minutos, y transferidos para un soporte cil&#237;ndrico de hierro, espec&#237;ficamente dibujado para permitir la completa exposici&#243;n de la cola del animal. En la regi&#243;n proximal de la cola se coloc&#243; el sensor (KSM-micr&#243;fono) conectado al plestim&#243;grafo.</p>
      <p>
        <bold>Evaluaci&#243;n morfol&#243;gica y funcional por el ecocardiograma</bold>
      </p>
      <p>Tras 24 horas del final del per&#237;odo de observaci&#243;n, los animales fueron sometidos al estudio ecocardiogr&#225;fico. Se emple&#243; el equipo de Philips (modelo TDI 5500) dotado de transductor multifrecuencial hasta 12 MHz. Se tomaron las medidas de las estructuras card&#237;acas de acuerdo con los requisitos de la <italic>American Society of Echocardiography</italic><sup>15</sup>. El mismo observador hizo las mediciones, sin conocer cu&#225;les grupos pertenec&#237;an los animales.</p>
      <p>
        <bold>Estudio morfom&#233;trico</bold>
      </p>
      <p>Tras el estudio ecocardiogr&#225;fico, se sacrificaron a los animales mediante administraci&#243;n de pentobarbitol. La relaci&#243;n entre el peso de los ventr&#237;culos (izquierdo y derecho), ajustado por el peso corporal de los animales, se utiliz&#243; como par&#225;metro de hipertrofia mioc&#225;rdica<sup>16,17</sup>. Las mediciones se llevaron a cabo por el mismo observador, sino conocer cuales grupos pertenec&#237;an los animales.</p>
      <p>
        <bold>M&#233;todo estad&#237;stico</bold>
      </p>
      <p>Las comparaciones se realizaron por medio de la ANOVA de una v&#237;a, complementadas por la prueba de Tukey, cuando los datos presentaron distribuci&#243;n normal. Cuando los datos no presentaron distribuci&#243;n normal, las comparaciones entre los grupos se llevaron a cabo mediante el test de Kruskal-Wallis. Los datos fueron expresados en promedio &#177; desviaci&#243;n est&#225;ndar (para distribuci&#243;n normal) o mediana con el percentil 25 y el percentil 75 (para distribuci&#243;n no normal). El nivel de significancia fue del 5%. Los an&#225;lisis estad&#237;sticos se hicieron con el programa SigmaStat <italic>for</italic> Windows v3.5 (SPSS Inc, Chicago, IL).</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Respecto a la frecuencia cardiaca, los animales del Grupo BB presentaron menores valores con relaci&#243;n a los animales fumadores (C = 358 &#177; 74 lpm, F = 374 &#177; 53 lpm, BB = 297 &#177; 30 lpm; P = 0,02). Por otro lado, no observamos diferencia significativa en la PAS de la cola entre los animales de los tres grupos (C = 117 (110-120) mmHg, F = 127 (110-140) mmHg, BB = 117 (115-120) mmHg; P = 0,142). </p>
      <p>Los datos del estudio ecocardiogr&#225;fico est&#225;n en la <xref ref-type="table" rid="tab01-body2">Tabla 1</xref>. Los an&#225;lisis morfol&#243;gicos mostraron que los animales del Grupo F presentaron mayores di&#225;metros diast&#243;licos del ventr&#237;culo izquierdo (VI), ajustados al peso corporal (PC), en relaci&#243;n con los animales control (C = 18,6 &#177; 3,4 mm/kg, F = 22,8 &#177; 1,8 mm/kg, BB = 21,7 &#177; 1,8 mm/kg; P = 0,003). Por otro lado, el grupo BB present&#243; valores intermediarios de esa variable, ya que no hubo diferencia en comparaci&#243;n a los valores tanto de C como de F. </p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0479-00011-gt01-es.jpg"/></table-wrap>
      <p>El an&#225;lisis funcional evidenci&#243; que los animales del Grupo F presentaron mayores di&#225;metros sist&#243;licos del ventr&#237;culo izquierdo, ajustado al PC (C = 8,6 &#177; 2,1 mm/kg, F = 11,3 &#177; 1,3 mm/kg, BB = 9,9 &#177; 1,2 mm/kg; P = 0,004) con relaci&#243;n a los animales control. Nuevamente, el Grupo BB present&#243; valores intermediarios de esa variable, ya que no hubo diferencia en comparaci&#243;n a los valores tanto de C como de F. De igual manera, hubo tendencia de menor fracci&#243;n de eyecci&#243;n (C = 0,90 &#177; 0,03 %, F = 0,87 &#177; 0,03 %, BB =0,90 &#177; 0,02 %; P = 0,07) en el Grupo F en comparaci&#243;n con C y tendencia de menor porcentaje de acortamiento (C = 54 &#177; 5, F = 50 &#177; 4, BB = 54 &#177; 4; P = 0,09) en el Grupo F, que los animales de los Grupos C y BB. No fueron encontradas diferencias con relaci&#243;n a las otras variables.</p>
      <p>En lo que toca a las variables morfom&#233;tricas cardiacas (<xref ref-type="table" rid="tab02-body2">Tabla 2</xref>), los animales del grupo BB presentaron tendencia de menores valores del peso del VI ajustado por el peso del cuerpo de los animales (VI/PC), con relaci&#243;n a los animales fumadores (C = 1,94 (1,87 - 1,97) mg/g, F = 2,03 (1,9-2,1) mg/g, BB = 1,89 (1,86-1,94) mg/g; P = 0,09). No se detectaron diferencias respecto a las otras variables.</p>
      <table-wrap id="tab02-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0479-00011-gt02-es.jpg"/></table-wrap>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Este estudio tuvo por objeto analizar el efecto de la administraci&#243;n de betabloqueante en el proceso de remodelaci&#243;n ventricular, inducido por la exposici&#243;n al humo de cigarrillo en ratas. Los resultados mostraron que el bloqueo de los receptores adrenergicos beta fue seguido de atenuaci&#243;n de algunas alteraciones morfol&#243;gicas y funcionales causadas por el tabaquismo. </p>
      <p>Alteraciones de la geometr&#237;a, volumen, masa y constituci&#243;n del coraz&#243;n, en respuesta a la agresi&#243;n mioc&#225;rdica o a las alteraciones en las condiciones de la carga, han sido estudiadas con el nombre de remodelaci&#243;n cardiaca<sup>1-3</sup>. Se acepta que la hipertrofia y el aumento de la cavidad desempe&#241;an rol importante en el proceso de remodelaci&#243;n. Nuestros datos confirman estudios previos<sup>4-9</sup> en que el tabaquismo fue seguido por aumento de la cavidad ventricular en el modelo de la rata. Adicionalmente, uno de los hallazgos importantes del presente estudio fue que la administraci&#243;n de propranolol, un betabloqueante no selectivo (con acci&#243;n y receptores &#946;1 y &#946;2) result&#243; en valores intermediarios del di&#225;metro diast&#243;lico del VI, en comparaci&#243;n a los animales fumadores y controles. Inicialmente, no fueron encontradas diferencias entre los animales BB y los fumadores. Sin embargo, los valores de BB tambi&#233;n no fueron diferentes de los animales control. As&#237;, nuestros datos permiten sugerir que el propranolol no previno, sino atenu&#243; el aumento de la cavidad inducido por el tabaquismo. </p>
      <p>Otro aspecto relevante se refiere al hecho de que, cl&#225;sicamente, el proceso de remodelaci&#243;n est&#225; asociado a diferentes grados de disfunci&#243;n ventricular. Inicialmente, las alteraciones morfol&#243;gicas caracter&#237;sticas de la remodelaci&#243;n se pueden considerar como adaptativas ante las nuevas condiciones de carga a las cuales el coraz&#243;n agredido se somete. Sin embargo, cr&#243;nicamente, pueden ocurrir alteraciones gen&#233;ticas, moleculares y celulares cardiacas que son capaces de conllevar el empeoramiento progresivo de la funci&#243;n ventricular<sup>1-3</sup>. Nuestros datos est&#225;n en conformidad con ese concepto, ya que el aumento del di&#225;metro diast&#243;lico del VI con el tabaquismo fue seguido de empeoramiento de &#237;ndices de la funci&#243;n ventricular izquierda, como el di&#225;metro sist&#243;lico final, fracci&#243;n de eyecci&#243;n y porcentaje de acortamiento del VI. Un aspecto a tenerse en cuenta est&#225; referido al hecho de que el propranolol result&#243; en valores intermediarios entre los animales fumadores y los animales control. As&#237;, podemos inferir que la administraci&#243;n de betabloqueante no previno, sino atenu&#243; las alteraciones funcionales inducidas por el tabaquismo. Ese efecto es todav&#237;a m&#225;s relevante teni&#233;ndose en cuenta que los animales tratados con propranolol presentaban menor frecuencia cardiaca. Fisiol&#243;gicamente, la reducci&#243;n de la frecuencia cardiaca est&#225; asociada con la disminuci&#243;n de los valores de los &#237;ndices de eyecci&#243;n ventricular, independientemente de variaciones del estado contr&#225;ctil del miocardio.</p>
      <p>Los mecanismos responsables de las alteraciones morfol&#243;gicas y funcionales cardiacas, inducidas por la exposici&#243;n al humo del cigarrillo no est&#225;n completamente aclarados. Hay evidencias suficientes mostrando que el mon&#243;xido de carbono est&#225; asociado con apoptosis, disfunci&#243;n cardiaca, hipertrofia y dilataci&#243;n de la c&#225;mara ventricular izquierda tras el infarto experimental<sup>18,19</sup>. Trabajo anterior en el modelo de rata mostr&#243; que la administraci&#243;n de antioxidante atenu&#243; la remodelaci&#243;n inducida por el tabaquismo, sugiriendo que el estr&#233;s oxidativo tiene participaci&#243;n fisiopatol&#243;gica en las alteraciones cardiacas provocadas por el humo<sup>6</sup>. De otra manera, estudios previos, con per&#237;odos de observaci&#243;n mayores que el del presente trabajo (4 y 6 meses), no observaron alteraciones en el PO<sub>2</sub> y en el porcentaje de saturaci&#243;n de la hemoglobina por el O<sub>2</sub><sup>5,9</sup>. As&#237;, hipoxemia cr&#243;nica y alteraciones en la viscosidad sangu&#237;nea secundarias la hipoxia, potenciales candidatos que podr&#237;an explicar los resultados de nuestro estudio, probablemente no tiene participaci&#243;n en la fisiopatolog&#237;a de las alteraciones inducidas por el cigarrillo. De igual manera, no fue detectada asociaci&#243;n entre la remodelaci&#243;n cardiaca inducida por el tabaquismo y la activaci&#243;n de metaloproteinasas 2 y 9<sup>8</sup>. Otro mecanismo potencial est&#225; asociado al hecho de que datos anteriores mostraron que la administraci&#243;n de nicotina en ratas conscientes result&#243; en vasoconstricci&#243;n. As&#237;, la simpatectomia aboli&#243; los efectos vasoactivos de la nicotina<sup>20</sup>. En el mismo modelo, el humo de cigarrillo caus&#243; elevaci&#243;n de los niveles de endotelina-1<sup>21</sup> y la administraci&#243;n de antagonista selectivo de los receptores A de la endotelina atenu&#243; la respuesta de presi&#243;n inducida por la nicotina<sup>22</sup>. En otro estudio, la administraci&#243;n de nicotina disminuy&#243; la s&#237;ntesis de prostaciclina por el endotelio vascular<sup>23</sup>. Adicionalmente, la administraci&#243;n de antagonista de la vasopresina atenu&#243; la vasoconstricci&#243;n inducida por nicotina en los vasos sangu&#237;neos de la piel<sup>24</sup>. En nuestro trabajo, sin embargo, los animales expuestos al humo del cigarrillo y tratados con propranolol no presentaron diferencias en los niveles de presi&#243;n arterial en relaci&#243;n a los animales no tratados. De esa manera, nuestros datos sugieren que la atenuaci&#243;n de la remodelaci&#243;n causada por el propranolol no fue resultado de los efectos de la medicaci&#243;n en la presi&#243;n arterial.</p>
      <p>Debemos tener en cuenta que la activaci&#243;n neurohumoral podr&#237;a, por mecanismos autocrinos y paracrinos, resultar en alteraciones en v&#237;as de se&#241;alizaci&#243;n intracelulares<sup> 12,25</sup>. La cl&#225;sica subdivisi&#243;n de receptores &#946;-adrenergicos establece tres subtipos: &#946;1, &#946;2 y &#946;3 que activan la adenilciclasa, por medio de la prote&#237;na G, aumentando los niveles de AMP c&#237;clico, con posterior est&#237;mulo de la prote&#237;na quinasa A. &#201;sta, a su vez, causa la fosforilaci&#243;n de diversas prote&#237;nas que modulan la contractilidad (por ejemplo: canales L de calcio, fosfolamban, troponina I, receptores de rianodina, SERCA2a) y la remodelaci&#243;n cardiaca (fosfatidil inositol 3-quinasa, factores de crecimiento, ERK, quinasas activadas por mit&#243;genos, entre otros). As&#237;, el bloqueo de receptores &#946;-adrenergicos est&#225; asociado a una menor remodelaci&#243;n secundaria a varios est&#237;mulos, tanto en estudios experimentales como cl&#237;nicos<sup>12,25</sup>. Nuestros datos est&#225;n en conformidad con esas evidencias, ya que hubo atenuaci&#243;n de la remodelaci&#243;n inducida por la exposici&#243;n al humo del cigarrillo. Tom&#225;ndose en consideraci&#243;n que no hubo diferencia en los niveles de presi&#243;n entre los animales de los tres grupos, nuestros datos sugieren que la atenuaci&#243;n de la remodelaci&#243;n causada por el propranolol probablemente implic&#243; v&#237;as de se&#241;alizaci&#243;n intracelulares moduladas por los receptores &#946;-adrenergicos que, sin embargo, probablemente no fueron como consecuencia de efectos hemodin&#225;micos. </p>
      <p>Un aspecto relevante del presente trabajo est&#225; referido a las implicaciones cl&#237;nicas de los nuestros resultados. Hay evidencias de que el tabaquismo puede resultar en alteraciones morfol&#243;gicas y funcionales cardiacas en humanos. Por ejemplo, en el estudio observacional CARDIA, fumadores tuvieron mayor masa ventricular izquierda, en comparaci&#243;n con no fumadores, evaluados por ecocardiograma<sup>26</sup>. Adicionalmente, la inhalaci&#243;n aguda del humo de cigarrillo fue seguido por disturbios de la funci&#243;n diast&#243;lica, en pacientes con documentada enfermedad arterial coronaria<sup>27,28</sup>. De ese modo, hay la posibilidad de que la administraci&#243;n de betabloqueante pueda interferir en las alteraciones inducidas por el tabaquismo tambi&#233;n en humanos.</p>
      <p>Por fin, nuestros resultados se deben analizar teni&#233;ndose en cuenta potenciales limitaciones. En primer lugar, las variables analizadas fueron solo par&#225;metros ecocardiogr&#225;ficos y de peso. Nuestro trabajo no evalu&#243; otras variables implicadas en el proceso de remodelaci&#243;n como, por ejemplo, contenido de col&#225;geno intersticial. Otro aspecto es que apenas algunas de las variables analizadas fueron estad&#237;sticamente diferentes. Ese hecho sucedi&#243;, probablemente, como resultado del peque&#241;o n&#250;mero de nuestra muestra. Sin embargo, pese a esas limitaciones, creemos que las variables analizadas fueron suficientes para caracterizar el proceso de remodelaci&#243;n inducido por el tabaquismo y revelar efectos biol&#243;gicos con el propranolol.</p>
      <p>En conclusi&#243;n, la administraci&#243;n de propranolol no previno, sino atenu&#243; algunas de las variables de la remodelaci&#243;n ventricular inducida por la exposici&#243;n al humo del cigarrillo en ratas.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Effects of the administration of beta-blockers on ventricular remodeling induced by cigarette smoking in rats</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: The role of the adrenergic system on ventricular remodeling induced by cigarette smoking is unknown. OBJECTIVES: To investigate the influence of propranolol on ventricular remodeling induced by exposure to tobacco smoke. METHODS: Rats were divided into three groups: 1) C, n=10 - control group; 2) F, n=10 - animals exposed to tobacco smoke; 3) BB, n=10 - animals receiving propranolol and exposed to tobacco smoke (40 mg/kg/day). After 2 months, the animals underwent echocardiographic and morphometric analyses. One-way ANOVA (mean &#177; standard deviation) or the Kruskal-Wallis test (median and interquartile interval) was used. RESULTS: Group BB showed a lower heart rate than group F (C = 358 &#177; 74 bpm, F = 374 &#177; 53 bpm, BB = 297 &#177; 30; P = 0.02). Group F showed greater end-diastolic diameters (C = 18.6 &#177; 3.4 mm/kg, F = 22.8 &#177; 1.8 mm/kg, BB = 21.7 &#177; 1.8 mm/kg; P = 0.003) and left ventricular (LV) end-systolic diameters (C = 8.6 &#177; 2.1 mm/kg, F = 11.3 &#177; 1.3 mm/kg, BB = 9.9 &#177; 1.2 mm/kg; P = 0.004), adjusted for body weight (BW) and a tendency towards a lower ejection fraction (C = 0.90 &#177; 0.03, F = 0.87 &#177; 0.03, BB =0.90 &#177; 0.02; P = 0.07) than group C. Group BB showed a tendency towards a lower LV/BW ratio than group F (C = 1.94 (1.87 - 1.97), F = 2.03 (1.9-2.1) mg/g, BB = 1.89 (1.86-1.94); P = 0.09). CONCLUSION: Administration of propranolol attenuated some of the variables of ventricular remodeling induced by the exposure to tobacco smoke in rats.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Adrenergic beta-antagonists</kwd>
        <kwd>ventricular remodeling</kwd>
        <kwd>smoking</kwd>
        <kwd>rats</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="tx-body3">
          <label>
            <bold>Effects of the administration of beta-blockers on ventricular remodeling induced by cigarette smoking in rats</bold>
          </label>
          <p>
            <bold>Daniella R. Duarte; Lucienne C. Oliveira; Marcos F. Minicucci; Paula S. Azevedo; Beatriz B. Matsubara; Luiz S. Matsubara; &#193;lvaro O. Campana; Sergio A. R. Paiva; Leonardo A. M. Zornoff</bold>
          </p>
        </fn>
      </p>
      <p>Faculdade de Medicina de Botucatu, Botucatu, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> The role of the adrenergic system on ventricular remodeling induced by cigarette smoking is unknown.</p>
      <p><bold>OBJECTIVES:</bold> To investigate the influence of propranolol on ventricular remodeling induced by exposure to tobacco smoke.</p>
      <p><bold>METHODS:</bold> Rats were divided into three groups: 1) C, n=10 &#150; control group; 2) F, n=10 - animals exposed to tobacco smoke; 3) BB, n=10 - animals receiving propranolol and exposed to tobacco smoke (40 mg/kg/day). After 2 months, the animals underwent echocardiographic and morphometric analyses. One-way ANOVA (mean &#177; standard deviation) or the Kruskal-Wallis test (median and interquartile interval) was used.</p>
      <p><bold>RESULTS:</bold> Group BB showed a lower heart rate than group F (C = 358 &#177; 74 bpm, F = 374 &#177; 53 bpm, BB = 297 &#177; 30; P = 0.02). Group F showed greater end-diastolic diameters (C = 18.6 &#177; 3.4 mm/kg, F = 22.8 &#177; 1.8 mm/kg, BB = 21.7 &#177; 1.8 mm/kg; P = 0.003) and left ventricular (LV) end-systolic diameters (C = 8.6 &#177; 2.1 mm/kg, F = 11.3 &#177; 1.3 mm/kg, BB = 9.9 &#177; 1.2 mm/kg; P = 0.004), adjusted for body weight (BW) and a tendency towards a lower ejection fraction (C = 0.90 &#177; 0.03, F = 0.87 &#177; 0.03, BB =0.90 &#177; 0.02; P = 0.07) than group C. Group BB showed a tendency towards a lower LV/BW ratio than group F (C = 1.94 (1.87 &#150; 1.97), F = 2.03 (1.9-2.1) mg/g, BB = 1.89 (1.86-1.94); P = 0.09).</p>
      <p><bold>CONCLUSION:</bold> Administration of propranolol attenuated some of the variables of ventricular remodeling induced by the exposure to tobacco smoke in rats.</p>
      <p><bold>Key Words:</bold> Adrenergic beta-antagonists / administration &amp; dosage; ventricular remodeling; smoking; rats.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Cardiac remodeling can be defined as variations in size, geometry, composition, and function of the heart. This process is a response to several stimuli, including myocardial infarction, systemic arterial hypertension, valvular disease, and genetic mutations<sup>1-3</sup>. Ventricular remodeling is initially an adaptive compensatory process, since morphological alterations may restore or preserve cardiac function in response to different aggressions. Chronically, however, the ventricular remodeling process leads to a progressive decline of ventricular function, signs and symptoms of heart failure, and death<sup>1-3</sup>.</p>
      <p> Recently, several studies have shown that in the rat model, exposure to tobacco smoke results in cardiac remodeling characterized by an increase in the left ventricular cavity, myocyte hypertrophy, and reduced ventricular function<sup>4-9</sup>. However, the mechanisms involved in this phenomenon are not yet determined. Among the mechanisms involved in the modulation of the functional and morphological changes occurring in different models of aggression, the activation of the adrenergic system seems to play a significant role<sup>10,11</sup>. Thus, studies have shown that the use of beta-blockers attenuates cardiac remodeling in different experimental and clinical models<sup>12</sup>. Nevertheless, the effects of the administration of beta-blockers on the remodeling induced by exposure to tobacco smoke are unknown.</p>
      <p>Therefore, the aim of this study was to investigate the influence of the administration of propranolol on ventricular remodeling induced by exposure to tobacco smoke in rats.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>The experimental protocol of this study was approved by the Committee for Ethics in Animal Experimentation at Faculdade de Medicina de Botucatu, and it complies with the Ethical Principles of Animal Experimentation defined by the Brazilian College of Animal Experiments.</p>
      <p>
        <bold>Protocol and experimental groups</bold>
      </p>
      <p>Wistar male rats weighing 200-230g were allocated to 3 experimental groups: 1) Group C, n=10 &#150; consisting of animals not exposed to tobacco smoke; 2) Group F, n=10 &#150; consisting of animals exposed to tobacco smoke during 2 months; 3) Group BB, n=10 &#150; consisting of animals exposed to tobacco smoke during 2 months and receiving propranolol (40 mg/kg/day) diluted in drinking water. A prior study evidenced that this dose has biological effects in a rat model<sup>13</sup>. As the medication was diluted in water, the daily intake of food and water by the animals was monitored.</p>
      <p>
        <bold>Exposure to tobacco smoke</bold>
      </p>
      <p>In order to expose the animals to tobacco smoke, we used the method proposed by Wang et al<sup>14</sup> which has already been standardized at our laboratory<sup>4-9</sup>. At the end of the experimental study period, the animals had been exposed to smoke equivalent to 40 cigarettes/day. With this methodology, exposure to tobacco smoke results in cardiac remodeling and functional worsening<sup>4-9</sup>. </p>
      <p>
        <bold>Tail systolic pressure</bold>
      </p>
      <p>Measurement of the systolic arterial pressure (SAP) of the tail was taken two weeks before slaughter. Animals of the smoking group were not exposed to tobacco smoke during a period of 24 hours before the measurements. A tail plethysmograph was used, which consisted of a polygraph (Byo-Sistem PE 300, NARCO) with a sensor placed in the proximal region of the tail, and an electro-sphygmomanometer which enabled graphical recording of arterial pressure. The animals were warmed in a wooden box at 37&#186;C with heat generated by two incandescent lamps for four minutes, and were then transferred to an iron cylindrical support especially designed to allow total exposure of the animal's tail. A sensor (KSM-microphone) was placed in the proximal region of the tail, and coupled to the plethysmograph. </p>
      <p>
        <bold>Echocardiographic evaluation of morphology and function</bold>
      </p>
      <p>Twenty-four hours after the end of the observation period, all animals underwent the echocardiographic study performed with a Philips device (TDI 5500 model), with a multi-frequency transducer up to 12 MHz. Cardiac structures were measured as per recommendations of the American Society of Echocardiography<sup>15</sup>. The measurements were taken by the same observer, who did not know which groups the animals belonged to.</p>
      <p>
        <bold>Morphometric study</bold>
      </p>
      <p>After the echocardiographic study, the animals were euthanized with pentobarbital. The ratio between the weight of the left and the right ventricles adjusted by body weight was used as a parameter of myocardial hypertrophy<sup>16,17</sup>. The measurements were taken by the same observer, who did not know which groups the animals belonged to.</p>
      <p>
        <bold>Statistical method</bold>
      </p>
      <p> Statistical comparisons were made using one-way ANOVA, followed by the Tukey test when data had a normal distribution. When the distribution was not normal, comparisons between the groups were made using the Kruskal-Wallis test. Data were expressed as means &#177; standard deviations (for normal distribution), or medians with 25<sup>th</sup> and 75<sup>th</sup> percentiles (for non-normal distribution). The significance level was 5%, and the statistical analyses were performed using the SigmaStat for Windows v3.5 software (SPSS Inc, Chicago, IL).</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>With regard to heart rate, animals in the BB group showed lower values as compared to smoking animals (C = 358 &#177; 74 bpm, F = 374 &#177; 53 bpm, BB = 297 &#177; 30 bpm; P = 0.02). On the other hand, no significant difference was observed in tail SAP among the animals of the three groups (C = 117 (110-120) mmHg, F = 127 (110-140) mmHg, BB = 117 (115-120) mmHg; <italic>p </italic>= 0.142). </p>
      <p><xref ref-type="table" rid="tab01-body3">Table 1</xref> shows the echocardiographic study data. Morphological analyses showed that the animals in group F had greater left ventricular (LV) diastolic diameters adjusted for body weight (BW) compared with those of control animals (C = 18.6 &#177; 3.4 mm/kg, F = 22.8 &#177; 1.8 mm/kg, BB = 21.7 &#177; 1.8 mm/kg; <italic>p</italic> = 0.003). On the other hand, the BB group showed intermediate values for this variable as there was no difference compared to those recorded for both the C and F groups. </p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0479-00011-gt01-en.jpg"/></table-wrap>
      <p>Functional analysis showed that the animals in group F had greater left ventricular (LV) systolic diameters adjusted for body weight (BW) (C = 8.6 &#177; 2.1 mm/kg, F = 11.3 &#177; 1.3 mm/kg, BB = 9.9 &#177; 1.2 mm/kg; <italic>p</italic> = 0.004) than those of the control animals. Once again, Group BB had intermediate values for this variable, as there was no difference compared to the values recorded for both the C and F groups. Likewise, there was a tendency towards a lower ejection fraction (C = 0.90 &#177; 0.03 %, F = 0.87 &#177; 0.03 %, BB =0.90 &#177; 0.02 %; P = 0.07) in group F as compared to group C, and a tendency towards a lower fractional shortening (C = 54 &#177; 5, F = 50 &#177; 4, BB = 54 &#177; 4; P = 0.09) in Group F than in the animals of Groups C and BB. No differences were recorded as to the other variables.</p>
      <p>As to the cardiac morphometric variables (<xref ref-type="table" rid="tab02-body3">Table 2</xref>), the animals in group BB showed a tendency towards lower LV weight values adjusted for body weight of the animals (LV/BW) when compared to the smoking animals (C = 1.94 (1.87 &#150; 1.97) mg/g, F = 2.03 (1.9-2.1) mg/g, BB = 1.89 (1.86-1.94) mg/g; P = 0.09). No differences were recorded for the other variables.</p>
      <table-wrap id="tab02-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0479-00011-gt02-en.jpg"/></table-wrap>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>The aim of this study was to analyze the effect of beta-blocker administration on left ventricular remodeling induced by exposure to tobacco smoke in rats. Results have shown that the blockage of beta-adrenergic receptors was followed by attenuation of some morphological and functional changes caused by tobacco smoking. </p>
      <p>Changes in the geometry, volume, mass, and constituents of the heart in response to myocardial aggression or to alterations in loading conditions, have been studied under the name of cardiac remodeling<sup>1-3</sup>. Hypertrophy and increased cavity size have been recognized as important players in the remodeling process. Our findings confirm prior studies<sup>4-9</sup> which showed that smoking was followed by an increase in left ventricular cavity size in the rat model. Additionally, one of the important findings of this study was that administration of propranolol, a non-selective beta-blocker (acting on &#946;1 and &#946;2 receptors), resulted in intermediate values of LV diastolic diameter when compared to smoking and control animals. At first, no differences were found between BB and smoking animals. However, BB values were not different from those of the control group animals. Thus, our data allows us to suggest that propranolol did not prevent, but rather attenuated the increase in cavity size induced by smoking. </p>
      <p>Another relevant aspect of cardiac remodeling is that, classically, the process is associated with different degrees of ventricular dysfunction. Initially, the characteristic morphological changes of remodeling may be considered adaptative in face of the new loading conditions to which the affected heart is subjected. Chronically however, genetic, molecular, and cellular changes may occur, resulting in progressive ventricular dysfunction<sup>1-3</sup>. Our data are consistent with this concept, since the increase in LV diastolic diameter induced by smoking was followed by worsening rates in left ventricular function, such as end-systolic diameter, ejection fraction, and LV fractional shortening. Another aspect to be considered is that propranolol resulted in intermediate values between smoking and control animals. Thus, it is possible to conclude that beta-blocker administration did not prevent, but attenuated the functional changes induced by smoking. This effect is even more significant if we consider that the animals treated with propranolol had lower heart rates. Physiologically, a reduced heart rate is associated with a decrease in ventricular ejection rate values, regardless of variations in the contractile status of the myocardium.</p>
      <p>The mechanisms responsible for cardiac morphological and functional changes induced by exposure to tobacco smoke have not been fully explained. There is sufficient evidence showing that carbon monoxide is associated with apoptosis, cardiac dysfunction, hypertrophy, and dilation of the left ventricular chamber after experimental myocardial infarction<sup>18,19</sup>. A prior study with a rat model showed that the administration of an antioxidant attenuated remodeling induced by smoking, suggesting that oxidative stress plays a pathophysiological role in the cardiac changes caused by tobacco smoking<sup>6</sup>. Conversely, prior studies, with periods of observation longer than that in this study (4 and 6 months), have not shown changes in PO<sub>2</sub> and in the percentage of hemoglobin saturation with O<sub>2</sub><sup>5,9</sup>. Thus, chronic hypoxemia and changes in blood viscosity secondary to hypoxia, potential explanations for the results in our study, may have not participated in the pathophysiology of the changes induced by smoking. Similarly, no association was found between cardiac remodeling induced by smoking and the activation of <bold>metalloproteinase-2 and -9</bold><sup>8</sup>. Another potential mechanism is associated with the fact that prior data have shown that the administration of nicotine to alert rats resulted in vasoconstriction. Thus, sympathectomy abolished the vasoactive effects of nicotine<sup>20</sup>. In the same model, tobacco smoke caused a rise in the levels of endothelin-1<sup>21</sup>, and the administration of a selective endothelin-A receptor antagonist attenuated the pressure response induced by nicotine<sup>22</sup>. In another study, the administration of nicotine reduced the synthesis of prostacyclin from the vascular endothelium<sup>23</sup>. Additionally, the administration of a vasopressin antagonist attenuated the vasoconstriction induced by nicotine in dermal blood vessels<sup>24</sup>. In our study, however, no differences were observed in the levels of arterial pressure of the animals exposed to tobacco smoke and treated with propranolol versus the animals that did not receive the treatment. Thus, our data suggest that the attenuation of remodeling caused by propranolol did not result from the effects of the drug on arterial pressure.</p>
      <p>We must remember that, due to autocrine and paracrine mechanisms, neurohumoral activation could result in changes in intracellular signaling pathways<sup>12,25</sup>. The classical subdivision of &#946;-adrenergic receptors defines 3 subtypes: &#946;1, &#946;2, and &#946;3 which activate adenyl cyclase through the G protein, increasing the levels of cyclic AMP with posterior stimulus by protein kinase A, which in turn causes phosphorylation of several proteins that modulate contractility (for instance: L-type calcium channels, <bold>phospholamban</bold>, troponin I, ryanodine receptors, SERCA2a) and cardiac remodeling (<bold>phosphatidylinositol 3-kinase</bold>, growth factors, ERK, <bold>mitogen-activated</bold> protein <bold>kinase</bold>, among others). Thus, blockage of &#946;-adrenergic receptors is associated with less cardiac remodeling secondary to several stimuli, both in experimental and clinical studies<sup>12,25</sup>. Our data are consistent with this evidence since there was attenuation of remodeling induced by exposure to tobacco smoke. Considering that no difference was observed in the pressure levels among the animals of the three groups, our data suggest that attenuation of the remodeling caused by propranolol probably involved intracellular signaling pathways modulated by &#946;-adrenergic receptors, but which most probably did not result from hemodynamic effects. </p>
      <p>An important aspect of this study refers to the clinical implications of our results. There is evidence that smoking may cause morphological and functional cardiac changes in humans. For instance, among the participants of the observational study CARDIA, smokers had a greater left ventricular mass than non-smokers as evaluated by echocardiogram<sup>26</sup>. Additionally, acute inhalation of cigarette smoke was accompanied by impairment of diastolic function in patients with documented coronary disease<sup>27,28</sup>. Therefore, it is possible that the administration of beta-blockers may interfere with the changes induced by smoking in humans as well.</p>
      <p>Finally, our results should be analyzed considering potential limitations in this study. First of all, the variables analyzed were merely echocardiographic and body weight parameters. Our study did not evaluate other variables involved in the remodeling process, such as interstitial collagen content. Another aspect is that only a few variables were statistically different, fact which was probably due to the small sample in our study. However, despite these limitations, we believe that the variables analyzed were sufficient to characterize the remodeling process induced by smoking and to show biological effects with propranolol. </p>
      <p>In conclusion, the administration of propranolol did not prevent, but did attenuate some of the ventricular remodeling variables induced by the exposure to tobacco smoke in rats.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
